Thailand Love Baby Reproductive Genetics Center - Analysis of Assisted Reproductive Genetic Testing Technology Features and Applicable Populations

===== Opening: Real Consultation Scenario =====

============================================================ Module G: The Most Easily Overlooked Details ============================================================

Easily Overlooked Details

When evaluating overseas reproductive centers, many people only focus on success rates and costs, often overlooking several key points:

• Technical version of the genetic testing platform: The read length, depth, and data analysis algorithms of NGS sequencing directly affect the accuracy of embryo screening. Different centers use different chip versions and data analysis pipelines.
• Timing of embryo biopsy and laboratory conditions: Biopsy procedures need to be performed in a stable culture environment. The laboratory's quality control standards, incubator stability, and embryologist experience all affect the embryo's potential for continued development.
• Completeness of genetic counseling: Whether detailed genetic counseling is provided before testing to help patients understand possible test results (including variants of uncertain significance, mosaicism, etc.) is a crucial part of decision-making.
• Documents and time window for cross-border medical treatment: Passport validity must be more than 6 months, the visa type must cover medical purposes, and some examination reports (such as chromosome karyotyping) have validity limits in some countries.
• Luteal phase support protocol for the transfer cycle: Different centers use different luteal phase support medications, administration routes (oral, vaginal gel, injection), and durations for frozen embryo transfer, affecting implantation success rates.

These details are often overlooked during initial consultations but can directly impact the smoothness and final outcome of the entire treatment process.

============================================================ Module A: Direct Answers to Questions ============================================================

Core Features and Applicable Populations

Thailand Love Baby Reproductive Genetics Center is a medical institution that deeply integrates assisted reproductive technology with embryo genetic testing. Its technical framework is built around the NGS (Next-Generation Sequencing) platform, enabling comprehensive chromosome screening (PGT-A) and single gene disease testing (PGT-M) on blastocysts.

When is it suitable to choose this center?

• Carriers or patients with single-gene genetic disorders: Such as thalassemia, spinal muscular atrophy (SMA), hereditary hearing loss, hemophilia, etc., requiring PGT-M to screen for embryos that do not carry the disease-causing gene.
• Carriers of chromosomal structural abnormalities: Including balanced translocations, Robertsonian translocations, inversions, etc., requiring PGT-SR to screen for chromosomally normal embryos.
• Repeated implantation failure or recurrent miscarriage: After excluding uterine factors, considering implantation failure due to embryonic chromosomal aneuploidy, PGT-A can screen for euploid embryos for transfer.
• Advanced maternal age (female ≥ 38 years): The rate of oocyte aneuploidy increases with age. PGT-A can reduce the risk of miscarriage caused by chromosomal numerical abnormalities.

When is it not suitable?

• Severely diminished ovarian function (AMH < 0.5 ng/mL, antral follicle count < 3): The number of retrieved eggs is too low, significantly reducing the probability of forming a blastocyst suitable for biopsy, and the benefit of PGT is limited.
• Untreated uterine factors: Conditions such as intrauterine adhesions, endometrial polyps, or submucosal fibroids should be addressed before directly proceeding with an ovulation induction and genetic testing cycle.
• Lack of psychological preparation for the complexity of genetic test results: Some embryos may show variants of uncertain significance (VUS) or mosaicism, requiring a full understanding of the uncertainties involved.

============================================================ Module I: Actual Procedure ============================================================

Medical Procedure and Schedule

From the initial consultation to the completion of the transfer, the entire cycle typically takes 3 to 4 months (including preliminary examinations, ovulation induction, genetic testing, and frozen embryo transfer). The phased procedure is as follows:

Phase	Key Activities	Estimated Time
Preliminary Preparation	Complete basic fertility assessment domestically (AMH, FSH, LH, antral follicle count), semen analysis, infectious disease screening, chromosome karyotyping; apply for passport (validity > 6 months), medical visa	1 to 2 months
First Visit and Registration	Arrive in Thailand, have a face-to-face consultation with the reproductive doctor, confirm the ovulation induction protocol, complete registration (requires marriage certificate, passport, translated copies of previous examination reports)	2 to 3 days
Ovulation Induction and Egg Retrieval	Ovulation induction medication for 8 to 12 days, monitoring follicle development during this period, schedule egg retrieval surgery (performed under intravenous anesthesia)	10 to 14 days
Embryo Culture and Biopsy	After ICSI fertilization, culture to blastocyst stage (day 5 to 6), perform trophectoderm biopsy on the blastocyst	5 to 6 days
Genetic Testing	Send biopsy samples to the NGS platform for PGT-A/PGT-M analysis, issue genetic report	10 to 14 days
Frozen Embryo Transfer	Select euploid/normal embryos based on test results, prepare the endometrium for transfer (natural cycle or hormone replacement cycle)	12 to 18 days
Post-Transfer Management	Check blood β-hCG 10 to 12 days after transfer to confirm pregnancy; continue luteal phase support until 10 to 12 weeks of gestation	Ongoing for 8 to 10 weeks

============================================================ Module D: Differences Across Age Groups ============================================================

Differences Across Age Groups

Age is an independent factor affecting assisted reproductive outcomes, and this holds true even at centers specializing in genetic testing.

• Female < 35 years: Relatively sufficient number of eggs retrieved, higher blastocyst formation rate. After PGT, the probability of screening at least 1 to 2 euploid embryos is higher. The main indication for choosing PGT in this age group is genetic disease prevention or chromosomal structural abnormalities.
• Female 35 to 37 years: Oocyte quality begins to decline, aneuploidy rate is approximately 30% to 40%. PGT-A can effectively screen for euploid embryos and reduce miscarriage rates, but be mentally prepared for the possibility of "no transferable embryos."
• Female 38 to 40 years: Aneuploidy rate rises to 50% to 60%, number of eggs retrieved decreases, may require multiple ovulation induction cycles to accumulate embryos. AMH and antral follicle count are important indicators for predicting egg yield.
• Female ≥ 41 years: Aneuploidy rate exceeds 70%, probability of obtaining a euploid embryo from a single ovulation induction cycle is significantly reduced. Some centers recommend considering egg donation as a backup option.

Regarding male age factors, although the sperm aneuploidy rate increases only slightly with age, an elevated sperm DNA fragmentation index (DFI) may affect blastocyst formation rate and the stability of genetic test results. It is recommended to evaluate this concurrently before the cycle.

============================================================ Module L: Interpretation of Key Examination Indicators ============================================================

Key Examination Indicators and Their Significance

Before deciding to travel to Thailand for a genetic testing cycle, the following indicators need careful evaluation:

Indicator	Normal/Reference Range	Impact on Decision-Making
AMH	1.0 to 4.0 ng/mL	Predicts ovarian response: < 1.0 ng/mL indicates diminished ovarian reserve, possible egg retrieval < 6, affecting the number of blastocysts available for biopsy
FSH (Day 2 to 3 of menstruation)	< 10 IU/L	> 12 IU/L indicates decreased ovarian function, requiring higher doses of ovulation induction medication, and egg retrieval numbers may be suboptimal
LH (Day 2 to 3 of menstruation)	2 to 8 IU/L	FSH/LH ratio > 2 may indicate reduced ovarian reserve
Antral Follicle Count (AFC)	5 to 15 (both ovaries combined)	Directly reflects the number of basal follicles. < 5 indicates limited egg retrieval, reducing the benefit of PGT
Semen Analysis	Concentration ≥ 15×10⁶/mL, PR ≥ 32%	Severe oligoasthenospermia may affect ICSI fertilization rate and blastocyst formation rate
Chromosome Karyotyping	46,XX or 46,XY	Confirms the presence of structural abnormalities like balanced translocations, Robertsonian translocations, determining the need for PGT-SR
DNA Fragmentation Index (DFI)	< 15%	DFI > 30% may affect blastocyst formation rate and the stability of genetic test results

The above indicators should be completed within 1 to 3 months before treatment. Some tests (like chromosome karyotyping) are valid for life, while hormonal indicators like AMH and FSH fluctuate with age and cycle.

============================================================ Module C: The Doctor's Perspective ============================================================

Key Evaluation Points from the Doctor's Perspective

In clinical decision-making, doctors typically assess whether a patient is suitable for an overseas reproductive center specializing in genetic testing based on the following four dimensions:

• Clarity of Indication: Is there a clear family history of genetic disease or chromosomal abnormality? Has genetic counseling and necessary family verification been performed? PGT without a clear indication constitutes overmedicalization.
• Match between Ovarian Function and Age: For older patients with low AMH, doctors may recommend 1 to 2 "trial ovulation induction" cycles to understand egg retrieval numbers and blastocyst formation rates before deciding on PGT.
• Transparency of Laboratory Quality Control: Doctors will check if the center publishes its quality control data, such as embryo culture rates, post-biopsy blastocyst survival rates, and PGT testing success rates, rather than just looking at the "final success rate."
• Depth of Genetic Counseling: Whether the center has professional genetic counselors who can explain complex situations like VUS, mosaicism, and mitochondrial diseases is key to assessing the maturity of a genetic testing center.

From clinical experience, those who truly benefit from PGT are patients with a clear genetic risk and reasonably good ovarian function. For those with significantly diminished ovarian function, the marginal benefit of PGT decreases.

============================================================ Module Q: Frequently Asked Questions ============================================================

Compilation of Frequently Asked Questions

• Can I still do overseas IVF with low AMH? Yes, but you need to be clearly informed that the number of eggs retrieved may be low, reducing the probability of forming a blastocyst suitable for biopsy. The doctor will comprehensively assess based on AMH value, AFC, and age, and in some cases, recommend accumulating embryos first.
• How far in advance should I prepare for overseas IVF? It is recommended to prepare at least 3 months in advance. This includes basic examinations (1 month), genetic counseling and family verification (1 to 2 months), document processing (1 month), and pre-cycle conditioning (1 to 2 months).
• What are the passport validity requirements for overseas IVF? Passport validity must be more than 6 months, with at least 2 blank visa pages. A medical visa requires a treatment invitation letter issued by the center.
• What materials are needed for registration for overseas IVF? Typically required: original passport, marriage certificate (notarized translation), all previous examination reports (including translations), and diagnostic certificates or genetic reports related to genetic diseases.
• What are the examination items for the male partner in overseas IVF? Includes semen analysis (routine + morphology + DFI), chromosome karyotyping, Y chromosome microdeletion (in cases of azoospermia or severe oligospermia), and infectious disease screening. In some cases, carrier screening for conditions like hereditary hearing loss may be added.
• What are the examination items for the female partner in overseas IVF? Includes AMH, FSH, LH, E2, thyroid function, infectious disease screening, chromosome karyotyping, and saline infusion sonography or hysteroscopy (if there is a history of uterine procedures).
• What should older women prepare for overseas IVF? In addition to the above examinations, it is recommended to add assessments of cardiac function, coagulation function, and glucose tolerance for metabolic evaluation, as the risk of pregnancy complications increases with advanced maternal age. Also, be mentally prepared for multiple cycles.

============================================================ Module F: Differences Between Hospitals ============================================================

Differences from Other Reproductive Centers

Compared to comprehensive reproductive centers or public hospital reproductive departments, the Thailand Love Baby Reproductive Genetics Center has the following differences:

Dimension	Genetic Testing Specialized Center	Comprehensive Reproductive Center
Technical Focus	Core focus on NGS genetic testing, full coverage of PGT-A/PGT-M/PGT-SR, laboratory configured around biopsy and sequencing	Full-service assisted reproduction, PGT is usually one of the available technologies, may not have its own sequencing platform
Target Population	Primarily for genetic disease prevention, chromosomal abnormalities, recurrent miscarriage; clear need for genetic testing	Covers all causes of infertility, including tubal factors, ovulation disorders, male factors, etc.; PGT accounts for only a portion
Genetic Counseling	Equipped with专职 genetic counselors, providing full-process report interpretation before, during, and after testing	In some centers, genetic counseling is provided by reproductive doctors concurrently, with limited depth
Process Flexibility	Standardized genetic testing pathway, tightly integrated from ovulation induction to transfer, suitable for patients with clear genetic needs	More flexible process, can adjust protocols based on patient's specific situation, e.g., addressing uterine issues before starting a cycle
Time and Cost	Genetic testing adds 2 to 3 weeks and additional testing costs (approximately 15,000 to 30,000 RMB)	When genetic testing is not needed, the cycle is shorter and total cost is lower

The choice of center depends on the patient's core needs. If the primary goal is to prevent genetic diseases, a specialized genetic testing center has advantages in technical depth and genetic counseling. If the issue is unexplained infertility or mild to moderate male factor, a comprehensive center may be more suitable.

============================================================ Closing: Risk Reminder ============================================================